EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections

Tushar Saha, Nikita Lyons, Deborah Bow Yue Yung, Miguel E Quiñones-Mateu, Daniel Pletzer, Shyamal C Das

European Journal of Pharmaceutics and Biopharmaceutics · 2024

DOI: 10.1016/j.ejpb.2023.12.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2024. Verfasst von Tushar Saha und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Otago, Dunedin, New Zealand. Hauptthemen laut MEDLINE: Respiratory Tract Infections, Anti-Infective Agents, Organoselenium Compounds, Isoindoles. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Otago, Otago Medical Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory tract infections (RTIs) are one of the leading causes of death globally, lately exacerbated by the increasing prevalence of antimicrobial resistance. While antimicrobial resistance could be overcome by developing new antimicrobial agents, the use of a safe repurposed agent having potent antimicrobial activity against various RTIs can be an efficient and cost-effective alternative to overcome the long and complex process of developing and testing new drugs. Ebselen, a synthetic organoselenium drug originally developed to treat noise-inducing hearing problems, has shown promising antimicrobial activity in vitro against several respiratory pathogens including viruses (e.g., SARS-CoV-2, influenza A virus) and bacteria (e.g., Mycobacterium tuberculosis, Streptococcus pneumoniae, and Staphylococcus aureus). Inhaled drug delivery is considered a promising approach for treating RTIs, as it can ensure effective drug concentrations at a lower dose, thereby minimizing the side effects that are often encountered by using oral or injectable drugs. In this study, we developed inhalable ebselen dry powder formulations using a spray-drying technique. The amino acids leucine, methionine, and tryptophan were incorporated with ebselen to enhance the yield and aerosolization of the dry powders. The amino acid-containing ebselen dry powders showed a better yield (37-56.4 %) than the amino acid-free formulation (30.9 %). All dry powders were crystalline in nature. The mass median aerodynamic diameter (MMAD) was less than 5 µm for amino acids containing dry powders (3-4 µm) and slightly higher (5.4 µm) for amino acid free dry powder indicating their suitability for inhalation. The aerosol performance was higher when amino acids were used, and the leucine-containing ebselen dry powder showed the highest emitted dose (84 %) and fine particle fraction (68 %). All amino acid formulations had similar cytotoxicity as raw ebselen, tested in respiratory cell line (A549 cells), with half-maximal inhibitory concentrations (IC50) between 100 and 250 μg/mL. Raw ebselen and amino acid-containing dry powders showed similar potent antibacterial activity against the Gram-positive bacteria S. aureus and S. pneumoniae with minimum inhibitory concentrations of 0.31 μg/mL and 0.16 μg/mL, respectively. On the other hand, raw ebselen and the formulations showed limited antimicrobial activity against the Gram-negative pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae. In summary, in this study we were able to develop amino-acid-containing inhalable dry powders of ebselen that could be used against different respiratory pathogens, especially Gram-positive bacteria, which could ensure more drug deposition in the respiratory tract, including the lungs. DPIs are generally used to treat lung (lower respiratory tract) diseases. However, DPIs can also be used to treat both upper and lower RTIs. The deposition of the dry powder in the respiratory tract is dependent on its physicochemical properties and this properties can be modulated to target the intended site of infection (upper and/or lower respiratory tract). Further studies will allow the development of similar formulations of individual and/or combination of antimicrobials that could be used to inhibit a number of respiratory pathogens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Tract InfectionsAnti-Infective AgentsOrganoselenium CompoundsIsoindolesHumansPowdersLeucineStaphylococcus aureusDrug RepositioningDry Powder InhalersRespiratory Aerosols and DropletsAdministration, InhalationParticle Size

Stichwörter der Autor:innen

Amino acidsAntibacterialCytotoxicityDry powderEbselenRespiratory infections

Substanzen

PowdersebselenLeucineAnti-Infective AgentsOrganoselenium CompoundsIsoindoles

Autor:innen und Institutionen

  • School of Pharmacy, University of Otago, Dunedin, New Zealand.
  • Department of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
  • School of Pharmacy, University of Otago, Dunedin, New Zealand. Electronic address: shyamal.das@otago.ac.nz.

Förderung

  • University of Otago
  • Otago Medical Research Foundation

Zitieren

APA

Saha, T., Lyons, N., Yue Yung, D. B., Quiñones-Mateu, M. E., Pletzer, D., & Das, S. C. (2024). Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2023.12.010

Vancouver

Saha T, Lyons N, Yue Yung DB, Quiñones-Mateu ME, Pletzer D, Das SC. Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections. European Journal of Pharmaceutics and Biopharmaceutics. 2024. doi:10.1016/j.ejpb.2023.12.010

BibTeX
@article{Saha2024,
  author = {Saha, Tushar and Lyons, Nikita and Yue Yung, Deborah Bow and Quiñones-Mateu, Miguel E and Pletzer, Daniel and Das, Shyamal C},
  title = {Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2024},
  doi = {10.1016/j.ejpb.2023.12.010}
}
Kostenlos starten →